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The Japanese Environmental Mutagen Society (JEMS) was established in 1972 by 147 members, 11 of whom are still on
the active list as of May 1, 2016. As one of them, I introduce some historic topics here. These include 1) establishment of
JEMS, 2) the issue of 2-(2-furyl)-3-(3-nitro-2-furyl)acrylamide (AF-2), 3) the Mammalian Mutagenicity Study Group (MMS)
and its achievements, and 4) the Collaborative Study Group of the Micronucleus Test (CSGMT) and its achievements. In
addition to these historic matters, some of which are still ongoing, a new collaborative study is proposed on adaptive
response or hormesis by mutagens. There is a close relationship between mutagens and carcinogens, the dose-response
relationship of which has been thought to follow the linear no-threshold model (LNT). LNT was fabricated on the basis of
Drosophila sperm experiments using high dose radiation delivered in a short period. The fallacious 60 years-old LNT is
applied to cancer induction by radiation without solid data and then to cancer induction by carcinogens also without
solid data. Therefore, even the smallest amount of carcinogens is postulated to be carcinogenic without thresholds now.
Radiation hormesis is observed in a large variety of living organisms; radiation is beneficial at low doses, but hazardous at
high doses. There is a threshold at the boundary between benefit and hazard. Hormesis denies LNT. Not a few papers
report existence of chemical hormesis. If mutagens and carcinogens show hormesis, the linear dose-response relationship
in mutagenesis and carcinogenesis is denied and thresholds can be introduced.
Keywords: AF-2, Collaborative Study Group of the Micronucleus Test, CSGMT, 2-(2-furyl)-3-(3-nitro-2-furyl)acrylamide,
JEMS, Linear no-threshold model, LNT, Mammalian Mutagenicity Study group, MMS, MutagenIntroduction
When the members of the board of trustees of the Japanese
Environmental Mutagen Society (JEMS) were asked if they
would contribute their papers to Environmental
Mutagen Research (EMR), the former title of Genes
and Environment (G&E), when they write papers,
more than half answered no. They would rather con-
tribute them to Mutation Research, Mutagenesis, or
Environmental and Molecular Mutagenesis. The main
reason was that papers in EMR were not cited in PubMed.
When I was the editor-in-chief of EMR (1998–1999), ICorrespondence: sutou@shujitsu.jp
Shujitsu University, 1-6-1 Nishigawara, Naka-ku, Okayama-Shi 703-8234, Japan
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(http://creativecommons.org/publicdomain/zetried to make EMR a PubMed-citation journal, but my
trials and efforts came to naught. EMR was a quarterly
magazine and consisted of Japanese and English articles. A
total annual number of original papers might not reach
the criteria of citation by PubMed. EMR was changed to
Genes and Environment (G&E), a fully English journal, in
2006. Minako Nagao, editor-in-chief, made a great contri-
bution to G&E. In spite of her ardent efforts, however,
citation in PubMed was not successful. The editor-in-
chief was replaced by Takashi Yagi in 2011, and M. Nagao
became the production editor. As she retired from this
position, I took over the job from her in 2014. As the pro-
duction editor, I looked through all of the accepted papers
and checked them for errors and for format, so as not tole is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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from me is the deletion of keywords from the title so as to
avoid duplication. G&E became an open access journal in
2015, and I was freed from the position of production edi-
tor. Recently, I was delighted to learn that PubMed decided
to cite G&E papers. From my viewpoint, this is a dream
come true and more congratulatory than the 10th anniver-
sary itself. As I am one of JEMS members from the start,
let me make some remarks on the occasion of the PubMed
citation and the 10th anniversary of G&E.
Memoir of establishing the Japanese environmental
mutagen society
JEMS was established at the National Education Center in
Tokyo on August 21, 1972. The number of participants at
the first meeting was 147. Active members are 11 as of
May 1, 2016. They are Hikoya Hayatsu, Yasumoto Kikuchi,
Taijiro Matsushima, Tohru Shibuya, Hiroyasu Shimada,
Takashi Sugimura, Noriho Tanaka, Hiroshi Tanooka, Hideo
Tezuka, Makoto Umeda, and I. At first, JEMS was started
as the Environmental Mutagen Research Association for
the first 6 years. The program and the list of participants at
the first meeting were in my hands; I offered them to the
JEMS’ office so as not to be lost.
The organizer-in-chief of the first JEMS meeting was
Yataro Tajima, who gave an opening address at 9:30. It
was followed by a congratulatory address by E.B. Freese,
the then president of the American Environmental
Mutagen Society. Fourteen papers were presented at the
meeting. Each speaker presented his paper for 25 min. It
may be of interest to learn what the top researchers at that
time spoke of. Japanese titles are translated into English.
Hikoyuki Yamaguchi (Tokyo University): Chromosomal
aberrations by antibiotics in plants, Hidetoshi Yoshida and
Yukimasa Shiraishi (National Institute of Genetics):
Chromosomal aberrations by cadmium in humans, Shigeo
Iwahara (National Institute of Health Sciences): Mutation
induction in bacteria by food-associated substances, F.J. de
Serres (National Institute of Environmental Health
Sciences): Mutation induction in radiation-sensitive
strains of Neurospora crassa, Sohei Kondo (Osaka
University): Molecular mechanisms of mutations,
Takeo Suzuki (Institute of Public Health): Hazardous sub-
stances in human environments, Tsuneo Kada (National
Institute of Genetics): Screening methods for chemical
mutagens based on the theories of chemical mutagenesis,
Yasuhiko Shirasu (Institute of Environmental Toxicology):
Toxicity issues of pesticides, Hideya Endo (Kyushu
University): Chemical carcinogenesis and mutation,
Mamoru Saito (Tokyo University): Roles of natural carcin-
ogens in the environment, Fuminori Yanagisawa (Tokyo
Medical and Dental University): Consideration of terato-
genicity by alkylbenzene sulfonate, Tsuyoshi Kajiwara
(Takeda Pharmaceutical Co. Ltd.): Mutagenesis testingand teratogenicity, Ujihiro Murakami (Institute for Devel-
opmental Research): relationship between teratogens,
mutagens, and carcinogens, and W.W. Nichols and R.C.
Miller (Institute for Medical Research, Camden): Ana-
phase as a cytogenetic method in mutagenicity testing.
A close relationship between mutagenicity and car-
cinogenicity was a major concern in these days. Carcino-
genicity testing was time-consuming, labor-intensive,
and costly. Researchers made efforts to develop detec-
tion methods for mutagens as substitutes for detection
of carcinogens. As a result, a widely used food additive
was found to be a mutagen and this created a social
problem as shown below.
2-(2-Furyl)-3-(3-nitro-2-furyl)acrylamide (AF-2)
boosted JEMS activity
Mutagenicity and carcinogenicity was the major issue of
AF-2 in the 2nd JEMS meeting, organized by Yataro
Tajima and held at the National Institute of Genetics in
Mishima City in 1973. Seven papers out of 17 were asso-
ciated with AF-2. Some insisted that AF-2 was not a car-
cinogen and others refuted this assertion. There was a
very hot debate. AF-2 is an amorphous reddish powder.
AF-2 is a stable wide-spectrum antibiotic, and bacteria
do not attain tolerance or resistance to it. It is effective
at very low dose levels and long-lasting. In 1965, AF-2
was substituted for nitrofurazone, a food additive ap-
proved in 1950, and used widely in foods such as hams,
sausages, tofu, sweetened bean paste, and so forth. AF-2
would be an ideal food preservative if it lacked muta-
genic and carcinogenic properties. The carcinogenic
potential of AF-2 was tested, and negative results were
obtained in Donryu rats and ICR/JCL mice [1]. AF-2
was found, however, to induce chromosomal aberrations
in cultured human cells [2] and showed mutagenic and
DNA-modifying effects on bacteria [3]. AF-2 spanned
two epochs in the history of mutation research. First, the
discovery of AF-2 mutagenicity forced a re-examination
of its carcinogenicity. As a result, AF-2 was found to be
carcinogenic in ddY mice [4], and AF-2 was prohibited
for use as a food additive in 1974. Second, while AF-2
was mutagenic in E. coli B/rWP2 Trp−, the inability to
detect AF-2 mutagenicity with S. typhimurium strains
TA1535, TA1536, TA1537 and TA1538 [3] prompted B.N.
Ames to develop the new tester strains, TA98 and TA100
[5]. The rodent micronucleus test of AF-2 reviewed by the
Gene-Tox Program was inconclusive and the test was
classified as “inadequate” [6]. We demonstrated that AF-2
is clastogenic in the micronucleus test using MA/Ae mice
[7], though its clastogenicity was weak.
Critical remarks were that AF-2 induced forestomach
cancer, but humans do not have the forestomach as
rodents do, and that doses of AF-2 were so high that
albino mice were colored by AF-2. The oral LD50 is
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centration of 0.2% in the diet (1/3 of LD50) for up to 2
years was not carcinogenic [1], but carcinogenic at
0.45% (3/4 of LD50) for 18 months [4]. Thus, AF-2 was
carcinogenic at high doses and not carcinogenic at low
doses. The issue of AF-2 presents a big contemporary
problem, i.e., whether or not results obtained with high
doses are proportionally applicable to responses with
low doses. In other words, are there thresholds in car-
cinogenesis? This will be discussed later.
Establishing the mammalian mutagenicity study
group and its achievements
It is not too much to say that JEMS’ activities are largely
supported by those of subgroups such as the Mammalian
Mutagenicity Study Group (MMS), the Bacterial Mutage-
nicity Study Group, and the Study Group of Mutation
Mechanisms. The Environmental Epigenomics Society
and the Study Group of Non-mutagenic Carcinogens have
suspended their activities at the present time. Since I was
involved in the establishment of MMS, let me have a say.
MMS was established in 1982 by merging the Dominant
Lethal Test Seminar (organizers: Kiyoshi Tsuchikawa,
Yasumoto Kikuchi, and Tohru Shibuya) and the Micronu-
cleus Test Research Association (organizers: Motoi
Ishidate, Jr. and Yasumoto Kikuchi). An ad hoc committee
held a meeting in February 1982, and adopted the name
of MMS. The objectives of MMS were to scrutinize
in vivo mutagenesis testing systems and, by supporting
development of the research area, to contribute to safety
evaluation in humans. At the meeting held at the occasion
of the 11th annual meeting of JEMS in October 1982, in
Shuzenji, organized by Yukiaki Kuroda, action programs
were adopted and sub-committees were formed: 1) to do
collaborative studies, 2) to have workshops, and 3) to
examine protocols. MMS decided to have biannual meet-
ings. MMS had the 69th meeting in December 2016, while
JEMS had the 45th meeting in this November 2016.
As for 1) to do collaborative studies, a spot test group
and a micronucleus test (MN) group were organized at
first. Collaborative studies by MMS have expanded to
more than 20 studies as follows: (1) Mouse spot test, (2)
Sex-related difference in MN, (3) Strain difference in MN,
(3) Administration route difference in MN, (4) Treatment
times in MN, (5) Peripheral blood MN using supravital
staining with acridine orange, (6) MN using IARC (Inter-
national Agency for Research on Cancer) carcinogen, (7)
Aging and spontaneous and induced MN, (8) Rat periph-
eral blood MN, (9) Examination of genotoxicity using
transgenic animals, (10) Development of MN using organs
other than the bone marrow such as the liver, intestine,
skin, and gonads, (11) Risk assessment of genotoxicity
with special reference to mitomycin C, (12) Development
of MN coupled with the 4-week repeat dosing test, (13)Toxicogenomics using mice and rats, (14) relationship be-
tween in vivo and in vitro genotoxicity and carcinogenicity
(ongoing), (15) In vitro MN using human cells, (16) Devel-
opment of MN using the liver of juvenile animals, (17)
Examination of in vitro and in vivo comet assays, (18)
Conduct of an international collaborative in vivo comet
assay using rats, (19) Development of MN using the liver
and digestive tracts of mature rats given repeated doses
(ongoing), and (20) Development of Pig-assay (ongoing).
The results of these collaborative studies have been
reported in more than 100 papers.
As for 2) to have workshops, we had a workshop on
how to judge and detect spots using the positive control
of stuffed mice before conducting the mouse spot test.
Kiyoshi Tutikawa was the main instructor. Several work-
shops were carried out before the conducts of MN. For
example, bone marrow samples from several mice treated
with mitomycin C were combined and stained by Makoto
Hayashi and slides were distributed to 25 participants. Re-
sults are shown in Fig. 1 of my review paper [8]. Although
some fluctuations were seen at the first trial, these work-
shops must have contributed to build up participants’
skills and to standardize methods of MN.
A workshop on chromosomal aberrations was also held.
On the basis of this workshop, an atlas book was pub-
lished [9]. Approximately 1,000 photos were supplied by
Yoshiaki Kimura and Shinya Hitotsumachi (Takeda
Pharmaceutical Co. Ltd.), Koji Kondo (Shionogi & Co.
Ltd.), Seiji Sato and Shizuyo Sutou (NRI Life Science),
Minoru Sawada and Toshio Sofuni (National Institute of
Health Sciences), Hiroyasu Shimada and Chiharu Hattori
(Daiichi Pharmaceutical Co., Ltd.), Noriho Tanaka and
Koji Yamakage (Food and Drug Safety Center); 180 photos
were selected from them. Texts of the atlas book were
written by Motoi Ishidate, Jr., Toshio Sofuni, and Makoto
Hayashi (National Institute of Health Sciences), and
Naomichi Inui (Japan Tobacco Inc.).
MMS had its own journal, MMS Communications
(MMSC) (ISSN 0918–5976). This was started as a kind
of newsletter. MMSC No. 1 was prepared on the occa-
sion of the 14th MMS meeting in November 1988. It
was then published annually until 1991 (No. 4). In 1992,
Nos. 5 and 6 were issued for the biannual MMS meet-
ings. The first original paper was published by Naohiko
Higashikuni and Shizuyo Sutou (ITOHAM FOODS Inc.)
in No. 7 issued in 1993 [10]. The Nos. 1–7 constitute
Vol. 1 of MMSC. Would-be No. 8 was issued in Novem-
ber 1993, but this volume was titled “Reference materials
for the 24th biannual MMS meeting” because it con-
tained original, unpublished papers that were going to
be contributed to other journals. As collaborative studies
went on, lots of data were accumulated and we felt a
need to have a medium in which to present our own
data. Biannual MMSC was opened to the public and
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were Makoto Hayashi, Takeshi Morita (Nippon Glaxo,
Ltd.), Shizuyo Sutou, and Hironobu Yajima (Snow Brand
Milk Products Co., Ltd.). MMSC published supplemental
issues twice. The first one contains details of two papers
(summaries of the 6th and 7th collaborative studies) that
were presented to the 6th International Conference on
Environmental Mutagens (ICEM) at Melbourne, in
February, 1993. This was distributed to the participants.
The second one contained presentations at the Tokyo
pre-meeting, held on December 7–8, 1992, for the Inter-
national Workshop on Standardization of Procedures in
Genetic Toxicology, the plenary session of which was
held at the 6th ICEM. MMSC was published biannually
until Vol. 4, 1996.
My colleagues and I published 10 papers in MMSC
[10–19]. After 1996, MMSC was merged to Mutation
Research. This merger left a contribution route to Muta-
tion Research through MMS. Contributors send their
manuscripts to one of MMSC editors, who ask two peer
reviewers to examine each of them. Peer-reviewed man-
uscripts are sent to the editor-in-chief of Mutation Re-
search. I have communicated several papers to Mutation
Research through this route. Now that G&E has become
a PubMed-citation journal, this route could be closed.
Establishing the collaborative study group of the
micronucleus test and its achievements
As mentioned above, a small group to examine MN
protocols was established at the Shuzenji meeting in
1982. Members were Hiroyasu Shimada (chief ), Makoto
Hayashi, Yoshisuke Nishi (Japan Tobacco Inc.), Tohru
Shibuya, Noriho Tanaka, and myself. We examined 9
guidelines including those of European Economic Commu-
nity (EEC), US Environmental Protection Agency (EPA),
Federal Republic of Germany (FRG), International Com-
mission for Protection Against Environmental Mutagen
and Carcinogen (ICPEMC), Japanese Ministry of Health
and Welfare (JMHW), Organisation for Economic Co-
operation and Development (OECD), and United Kingdom
Environmental Mutagenesis Society (UKEMS). Close exam-
ination of these protocols for about 2 years revealed that
these were not based on experimental data, but were
deduced mainly from chromosomal aberration tests. As a
result, we decided to carry out collaborative studies and to
make MN protocols that are based on data.
I proposed to conduct a collaborative study to examine
sex-related differences at first, because animal numbers
could be halved if there were no sex-differences or if the
differences were negligible. This proposal was suggested by
my research into sex-determination mechanisms conducted
at Susumu Ohno’s laboratory in City of Hope Research In-
stitute in 1980–1981. The sex difference [20] was followed
by strain difference [21], administration dosing difference[22], and so on. I was in charge of preparation of manu-
scripts for these early papers. The author was the Collab-
orative Study Group of the Micronucleus Test (CSGMT).
The total number of papers produced by collaborative stud-
ies is more than 100, but the exact number is not in my
hands.
The 5th ICEM was held at Case Western University,
Cleveland, Ohio, on July 10–15, 1989. I had a chance to
present our large body of MN data from CSGMT. The
audience seemed to be deeply impressed by our large body
of data. I think this provided a precedent for data-based
protocols and for international experimental collabora-
tions thereafter. After my presentation, Motoi Ishidate, Jr.
told me that I won fame internationally. I answered, not
me but CSGMT.
China had planned to hold the 6th ICEM in 1993;
however, the crackdown known as the Tiananmen
Square Massacre occurred on June 4, 1989. Chinese
troops with rifles and tanks killed unarmed Chinese
civilians in Beijing. The ICEM board decided not to
have the 6th ICEM in China, saying that an inter-
national meeting could not be held in such a barbar-
ous county. So the 6th ICEM was held in Melbourne
in 1993, hosted by the Australia and New Zealand
Environmental Mutagen Society (ANZEMS). The
Chinese Environmental Mutagen Society hosted the
International Symposium on Environmental Mutagen-
esis and Carcinogenesis in Shanghai in May 1991. I
was an invited speaker and presented a paper, “Strain
difference in the micronucleus induction among
different strains of mice with a special reference to
MS/Ae mice.”
F.J. de Serres, an editor of Mutation Research, asked
me via Motoi Ishidate, Jr. to review the achievements of
CSGMT. Earlier topics described above are shown more
precisely in this review paper published in 1996 [8]. This
might also be useful to learn the history of JEMS, MMS,
and CSGMT in early days.
Summary of achievements and characteristics of
MMS and CSGMT
1) MMS is one of sub-groups of JEMS and consists of
around 150 members. CSGMT is one of sub-groups of
MMS that carries out MN. The number of members
varies depending on subjects. MMS has biannual
meetings and results obtained by CSGMT and
other groups are reported there.
2) Workshops held before collaborative studies were
useful to propagate standard techniques, which
supported the acquisition of qualified data.
3) A body of qualified data contributed to the
establishment of domestic and international
protocols and guidelines, e.g., for the International
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Requirements for Registration of Pharmaceuticals
for Human Use (ICH) and OECD. Subjects
associated with regulatory sciences were of great
concern for industries, constituting a factor to invite
participants from industries.
4) A large number of participants made it possible to
collect lots of data in a limited period; the burden to
each participant was not so heavy and one could
take part in collaborative studies fairly easily.
Collaboration among governmental, academic, and
industrial researchers was readily achieved.
5) The results of collaborative studies were published
in journals. The publication provided the
participants with credit. I am not sure, but around
20 people might get the doctorate degree using
results of collaborative studies in part.
6) The domestic activities of MMS and CSGMT were
integrated, at least in part, into the international
framework of guideline setting.
This section is written mainly in the past tense. But
activities of MMS and CSGMT are still ongoing, and the
situation after changing from the past to the present
tense would mostly hold.
Proposal of a new collaborative study: adaptive
response or hormesis by chemicals
Fabricated linear no-threshold model
Muller discovered that X-rays can induce mutations
in Drosophila melanogaster [23]. Atomic bombs were
dropped on Hiroshima and Nagasaki in 1945. The
consequent fear of nuclear warfare might have sup-
ported the award of a Nobel Prize to him in 1946
because he believed that even the smallest amount of
radiation is hazardous to human genes. Muller knew
of the existence of a threshold, but he asserted that
there is no threshold dose in his Nobel Prize lecture
[24]. He defended his faked linear no-threshold
(LNT) model with the prestige of the Nobel Prize to
the bitter end.
Standard Oil Co. Inc. was established by John
Rockefeller in 1870. The Rockefeller Foundation (RF)
was threatened by the discovery of atomic energy. In
1954, RF chose to finance six projects to evaluate
atomic radiation. RF asked the U.S. National Academy
of Sciences (NAS) to organize the whole program,
which was conducted under the auspices of Bronk,
president of the Rockefeller University, president of
NAS, and an RF trustee. The Genetics Panel (GP)
was established in NAS in 1954 and was chaired by
Weaver, an RF officer. GP consisted of 17 members,
13 of whom were geneticists including Muller. Most
members believed that all doses of radiation wereharmful, irreversible, cumulative, and linearly acting,
no significant discussion occurred [25]. GP recom-
mended LNT on June 12, 1956 [26], abandoning the
threshold of 500 mGy/y since 1934. The next day, the
New York Times, owned by an RF trustee, reported
on LNT on the front page. Other media followed.
Soon after its publication, several leading biologists
asked GP to provide documentation to support the
LNT. GP informed the president of NAS, Bronk, that
it would not provide any documentation; right from
the start, they did not have relevant data.Conversion of genetic risk to cancer risk and from
radiation to chemicals
X-rays induced mutations at high doses in the Drosoph-
ila sex linked recessive lethal test and LNT was fabri-
cated on the data observed in insect sperm that lack
repair systems. Actually, responses to X-rays in Drosoph-
ila were not linear and showed thresholds and hormesis
[27]. Lewis concluded that radiation induces leukemia
using Atomic bomb survivors’ data [28]. The National
Council of Radiation Protection and Measurement
(NCRPM) proposed the use of LNT for cancer risk
assessment in 1958. In 1958, the U.S. Food and Drug
Administration (FDA) introduced the Delaney Clause,
which allows no carcinogens in foods. This ideal, zero-
risk rule was soon confronted with reality. Scientific
advancement demonstrated that there is no absolutely
safe food in the world; the unrealistic Delaney Clause
was abolished in 1996.
The Environmental Protection Agency of the U.S.A.
(EPA) is involved in the regulation of carcinogens
under several laws. As risk cannot be eliminated com-
pletely, EPA introduced a concept of balance between
risks and benefits [29]. For risk assessment of a sus-
pect carcinogen, experimental data using animals are
important. The data are estimated by assuming LNT,
i.e., linear no-threshold dose-response relationship. In
spite of accumulated scientific knowledge, LNT has
not been revised and a safe level of exposure has not
been set for chemical carcinogens still now.Lifespan study of atomic bomb survivors does not
support LNT
The most important data to support LNT are data of
Lifespan Study of atomic bomb survivors (LSS). The
Biological Effect of Ionizing Radiations (BEIR) of NAS
asserted that the dose-response relation in cancer risk
was linear and supported LNT [30]. The latest pub-
lished result of LSS [31] insists that the dose-
response relation is linear and there are no thresholds
(Fig. 1, a). Both LNT and LSS, however, harbor intrin-
sic defects.
Fig. 1 Excess relative risk (ERR) of solid cancer in atomic bomb survivors. a [31], L: linear fit, LQ: linear-quadratic fit, C+ and C−: 95% CI (confidence interval)
to L. Assumed ERR is 0.42 at age 70 when people of age 30 were exposed to 1 Gy (a, blue arrow). Inset shows ERR at dose range 0–0.6 Gy. See that only
one point is between C+ and C−, unusually low ERR at 0.4 and 0.6 Gy, and LQ (<2 Gy) comes under C− (green line). b [33], comparison
of conventional LNT (black lines) with a Bayesian semiparametric model (red lines). C+ and C− are 95% confidence interval for LNT and
95% credible interval for the semiparametric model. As for the definition of non-parametric data (filled circle), see the reference [33]. Inset
shows ERR at dose range 0–0.4 Gy. See that LNT has only one point between C+ and C−, while eight points (ERR at 0.6 Sv is not shown)
are located between C+ and C− in the Bayesian model, which predicts a threshold and hormesis. Significant increase of ERR is observed
over 0.1 Gy. Figures are presented with permission from Radiation Research (a) and John Wiley and Sons (b)
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the doses were estimated only for initial radiation,
within 1 min after the atomic bomb blast. The
residual radiation was neglected. It was twice as high
as the initial radiation and was carried to the ground
by black rain. Its effects must have lasted for days or
weeks. This means that cancer risk in the LSS is
largely overestimated.
2) “In-the-city-control” people, who entered Hiroshima
or Nagasaki after the atomic bomb blast and were
used as the negative control, were exposed to residual
radiation and would not be appropriate as the
negative control. Indeed, their cancer mortality rate
was less than that of people in the villages northwest
of Hiroshima because the “in-the-city-control” people
showed hormetic effects [32].
3) Both reports say that the linear-quadratic fit is better
than the linear fit (compare L and LQ in Fig. 1, a).
There is no statistical significance between the two,
so they insist that the dose-response is linear.
4) The BEIR and LSS reports depict dose range
between 0–2 Sv and 0–3 Sv dose ranges (Fig. 1, a),
respectively. The responses at higher doses, in which
the dose-response curve shows a downturn, are
omitted. The downturn directly negates the linear
dose-response.5) Doses <100 mSv are most important for our
daily life. There are no statistical significant
differences between the control and the atomic
bomb survivors at these doses. The BEIR report
combined all data points <100 mSv, to which
more than 80% survivors belong, together into
one point. This dishonest statistical trick was
successful in giving the impression that the dose-
response is linear and no thresholds exist. The LSS
report shows all data points. Alas, 12 out of 13 data
points <0.6 Sv are located outside the 95% confidence
interval (Fig. 1, a), suggesting that there is no linearity
in a low dose range.
6) Both the BEIR and LSS reports are based on
conventional parametric analyses. Some drawbacks
harbored in these analyses can be cleared when a
Bayesian semiparametric analysis is used. This new
analysis [33] shows that the dose-response curve is
rather S-shaped or sigmoidal than linear (Fig. 1, b,
red line) and there is a threshold (Fig. 1, b, inset).
Eight data points out of 13 are located inside the
95% credible interval (Fig. 1, b, inset), while only
one point is inside the 95% confidence interval by
the conventional analyses (Fig. 1, a, inset).
7) Both leukemia [34] and solid cancers [32] incidences
in the LSS are hormetic.
Sutou Genes and Environment  (2017) 39:9 Page 7 of 88) The atomic bomb survivors were exposed with high
doses and high dose-rate radiation, the effects of
which were critically hazardous as compare with
those of low doses and low dose-rate radiation as in
the case of Fukushima.
Thus, the LSS does not support LNT. Gene mutations,
induced by high-dose radiation in Drosophila sperm, led
fallaciously to LNT without relevant data. The failed
germ cell mutation hypothesis was applied to somatic
cell mutations by radiation without relevant data. LNT
is now fundamental basis for radiation-regulatory guide-
lines. Then, LNT was applied to chemical carcinogenesis
without relevant data. Thus, the smallest amount of car-
cinogens is proportionally carcinogenic on the basis of
unproven inference. The linear dose-response relation-
ship of chemical carcinogens without thresholds must be
reevaluated.
Proposal of a new collaborative study: adaptive response
or hormesis by chemicals
Recently, I commented on hormesis [35]. Adaptive re-
sponse, or more properly hormesis, is seen universally
in many organisms including atomic bomb survivors
[32, 34]. Living organisms have established efficient
defense mechanisms against radiation through the evolu-
tionary history of billions of years. Hormesis resembles
the immune responses. Vaccination with attenuated
viruses beforehand provides us with tolerance to virulent
viruses afterwards. Hormesis can be seen in the following
situations.
1) Radiation or chemicals are beneficial at low doses,
but hazardous at high doses.
2) Exposure to low doses beforehand gives enhanced
cell repair after exposure to high doses.
3) Exposure to X-rays gives tolerance to γ-rays. Exposure
to substance A beforehand gives tolerance to substance
B afterwards.
Hormesis must be applied to chemicals. Mutagens and
carcinogens would not follow the manner that LNT pre-
dicts. Many papers indicate the existence of chemical
hormesis. I proposed a new collaborative study on horm-
esis in mutagenesis at the 68th MMS meeting on June 17,
2016. Presently, a test chemical that is found to be muta-
genic in one of the mutagenicity testing methods, it is
branded as a mutagen. My expectation is that it might be
mutagenic at higher doses, but would be antimutagenic at
lower doses. In between higher and lower doses, there
must be thresholds. My proposal is to examine the situ-
ation experimentally. When mutagenic hormesis is
proven, a mutagen will be classified as a hormetic muta-
gen, indicating that the mutagen is not always hazardous.Many drug candidates might have been dropped off as
mutagens during developmental process, but hormetic
mutagens could be developed as drugs with less fear about
mutation or cancer induction. Changes of guidelines for
registration of drugs, cosmetics, pesticides, and so on are
expected in the future if hormetic mutagenesis is proven.
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